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Material and Methods: Using the institutional databases of 3 
large UK Cancer Centres (Belfast, Glasgow and Leeds), 
patients who had curative intent thoracic radiation for NSCLC 
during 2010 were identified. Baseline demographics were 
collated, along with details of initial irradiation, relapse and 
subsequent management. Summary statistics were generated 
detailing the incidence of re-irradiation, treatment intent of 
re-irradiation and dose fractionation used. 
 
Results: In total, 351 patients were identified who had 
curative intent radiation. Of these, 188 (54%) relapsed, 60 
with local relapse only. Eleven patients (18% of those with 
local relapse) received palliative re-irradiation to thorax for 
specific symptoms, with fractionation schemes including 
8Gy/1 fraction, 16Gy/2 fractions, 20Gy/5 fractions and 
30Gy/10 fractions. Four patients (6%) received radical re-
irradiation with curative intent using 55Gy/20 fractions (3 
patients) or 55Gy/5 fractions (1 patient). Thirty-five patients 
(58%) had no treatment at relapse and most were categorised 
unfit. Four patients had salvage radical surgery. The 
remainder had systemic therapy or palliative supportive care. 
Median time between initial radiotherapy and local relapse 
was 13.5 months (3-49 months). Median time from initial 
radiation and re-irradiation was 24 months (6-41 months). No 
excessive radiation related toxicity was reported. 
 
Conclusion: In this selected cohort, re-irradiation is used 
routinely for patients with NSCLC, both with palliative and 
curative intent for local failure following radical thoracic 
radiotherapy. Further investigation of re-irradiation is 
warranted to assess toxicity, optimise techniques used and 
improve patient accessibility. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
of lung tumors gives excellent local control but with higher 
rates of toxicity for organs at risk located close to the tumor. 
Treating centrally located tumors with SBRT with 3 fractions 
increases the risk of severe side effects especially when 
located near the proximal bronchial tree (PBT) known from 
earlier studies. We aimed to evaluate our current practice 
using 56 Gy in 8 fractions for tumors located centrally in the 
lung or close to other organs at risk (OAR) located more 
peripherally in the lung. 
 
Material and Methods: Medically inoperable patients treated 
with 56 Gy in 8 fractions from the 1th of June 2012 until the 
1th of September 2014 were reviewed and analyzed. The 
patients were deemed unfit for SBRT in 3 fractions or 
normally fractionated radiotherapy. For three patients this 
treatment was part of the Nordic Hilus Study 
 
Results: Fifty patients were treated with a median follow up 
of 23.7 months (12.5-38.4). For baseline characteristics, see 
table 1. Not all tumors were centrally located; some tumors 
were close to columna, the apex of the lung or invaded the 
thoracic wall. Six patients had a locally recurrence (12%) and 
15 distant recurrence (30%). Twenty-seven patients had died 
by the end of data analysis. Thirteen patients died of 
recurrent lung cancer. One patient died of another cancer. 
Two patients died suddenly without obvious cause. Eight 
patients died of other reasons, primary due to infections 
and/or known heart disease. Three patients died of 
hemoptysis probably due to bleeding from the main 
bronchus. Only one of these patients had an autopsy. This 
patient was re-irradiated with 30 Gy in 10 fractions because 
of recurrence overlapping the initial site. The 1 year survival 
was 76%, 2 year survival 41% and the 3 year survival was 38%. 
The median overall survival was 21.1 months (3.1 – 37.0). 
 
 
 
Conclusion: SBRT with 56 Gy in 8 fractions for lung cancer in 
relation to OAR are tolerable with an acceptable local 
recurrence of 12%. The three patients who died of 
hemoptysis had their tumor located close to the main 
bronchus. Treatment of SBRT close to the PBT is known to 
cause damage to the bronchus. Due to the retrospective 
format of the trial some side-effects may be underreported. 
It is challenging to treat tumors close to organs at risk and in 
particularly the bronchial three with a dose to achieve local 
control and without harming the PBT or close to OAR. 
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Purpose or Objective: Technique and indication of 
stereotactic fractionated radiotherapy (SBRT) has emerged 
rapidly during the last decade. Delineation, dose 
specification and constraints have been adjusted to updated 
evidence. Retrospective Quality Assurance (QA) of available 
prospective data was performed in order to reconsider 
recommendations and might reveal important insights for 
future treatment strategies. 
 
Material and Methods: Within a prospective monocenter 
phase II study (STIPRE) 100 patients, elderly or unfit for 
surgery, have been treated with SBRT for 120 pulmonary 
lesions ≤5cm between 02/2011 and 12/2014. Applied doses 
were 3X12.5 Gy (85 lesions), 5X7Gy (30),7X5Gy (1) 4X6.5 Gy 
(1), 5X6.5 Gy (1), 8X7.5 Gy (1), 12X4.5 Gy (1), prescribed to 
60% isodose in all but 2 patients. Delineation of organs at risk 
(OARs) was requested, however not specified in a detailed 
way in the trial protocol. Applying a moderate dose no 
constraints were provided in the protocol but derived from 
the evidence available at that time. SBRT plans had been 
evaluated by at least two experienced radiation oncologists 
before treatment. Within the retrospective QA process of the 
trial we now evaluated the maximal dose applied to OARs and 
analyzed those data with respect to the dose constraints of 
the recently launched EORTC 22113-08113 Lungtech trial. If 
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constraints were violated we re-checked correspondence of 
the structures to the delineation standards of the Lungtech 
protocol. Association of violations and the prospectively 
recorded toxicity was evaluated. 
 
Results: According to DVHs 111 SBRT plans did not violate 
any of the dose constraints requested in the Lungtech trial. 
For 7/100 patients SBRT plans exceeded the Lungtech dose 
constraint for the proximal bronchial tree of EqD2=74.8Gy to 
> 0.5cc, one of them additionally for the esophagus of 
EqD2=64 Gy. 6/7 patients showed an increase in dyspnea, 2 
of them died 3 and 9 months after SBRT, one after 
hemoptysis and subsequent pneumonia, the other after being 
hospitalized for unclear progressive dyspnea; in both cases 
association of G5 toxicity to SBRT cannot be excluded. 
 
Conclusion: Despite the lack of detailed specific constraints 
within the STRIPE trial OAR exposure did not largely differ 
from current practice in modern SBRT. However, these 
preliminary results underline the importance of the dose 
constraints for the main airways within the Lungtech trial and 
the necessity to continuously review and adjust treatment 
procedures to upcoming evidence, especially when employing 
new techniques. 
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Purpose or Objective: SABR for primary NSCLC is becoming 
increasingly popular as evidence is mounting for its 
equivalent long-term clinical outcomes and good overall 
tolerability. We review our toxicity against dosimetry and 
achievement of dose constraints (SABR UK Consortium). We 
suggest that dosimetric constraints alone cannot be used to 
prevent SABR related side effects. 
 
Material and Methods: Patients with stage I NSCLC treated 
with SABR between January 2014 and August 2015 were 
included in this single centre cohort study. They were 
planned using relaxed breathing 4D CT then treated using 
VMAT. Baseline and dosimetric data was retrospectively 
collected by a clinical oncologist or physicist from the 
radiotherapy records. Patients were followed up at 4 weeks 
then at 3 monthly intervals until 1 year. CT scans were 
performed 3 and 12 months post radiotherapy. Prospective 
data collection was performed at follow up visits for clinical 
outcomes and acute and late normal tissue toxicity (scored 
using CTCAE v 3.0). 
 
Results: 28 patients were included in the study with a 
median follow up of 10.4 months. 19 patients have attended 
for post radiotherapy CT scans with 84.2% showing 
radiological response as per RECIST. All patients were 
assessed for acute toxicity data, 3.5% (1/28) noted grade 2 
reaction. Data on late toxicity was available for 19 patients: 
26.3% (5/19) experienced grade 2-3, no grade 4 or 5 reactions 
were recorded. When adjusted for baseline function (late 
toxicity score minus baseline score) this fell to 15% (3/19). 
Other than chest wall (CW) tolerances all dosimetry criteria 
were met. 10.7% of plans exceeded tolerance to 30cc CW 
(>30/32) with no recorded episodes of ≥grade 2 CW pain in 
these patients. 71.4% of plans exceeded dose constraint to 
0.01cc CW (>37/39) only 5% (1/20) complained of CW pain. 
Dosimetric analysis for this patient revealed dose to 30cc of 
CW was 25.8 Gy (<32), dose to 0.01 cc of CW was 59.1 Gy 
(<39), volume of PTV and CW overlapping was 0.03 cc and % 
of PTV-CW overlapping was 0.21%. 
 
Conclusion: We are achieving low rates of moderate or 
severe toxicity. Despite achieving dose constraints, a small 
cohort of patients developed toxicity grade 2-3. We 
hypothesize that these patients could develop radiotherapy 
toxicity due to other idiosyncratic factors (genetic 
polymorphisms, microenvironment). Further studies are 
currently running to investigate other causative factors. 
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Purpose or Objective: The aim of this study is to evaluate 
efficacy and toxicity of stereotactic body radiation therapy in 
early stage medically inoperable non-small lung cancer. 
 
Material and Methods: Data from patients affected by 
medically inoperable stage I NSCLC treated with stereotactic 
body radiation therapy (SBRT) were prospectively recorded. 
Treatments were planned employing 4D-CT . The prescribed 
dose was modulated according to location of the lesion and 
tolerance of the surrounding organs at risk: 54 Gy in 3 
fractions for peripheral lesions, 60 Gy in 4 fractions for 
lesions adjacent to the chest wall, 60 Gy in 8 fractions for 
central lesions. The primary endpoints were local control and 
toxicity, secondary endpoint was survival. The follow-up 
examinations were performed with CT and/or PET-CT at 1, 3, 
6, 9 and 12 months after treatment and every 6 months 
subsequentely. Acute and late side effects were recorded 
according to RTOG morbidity Scoring Scale.  
 
Results: From 2009 to 2014, 65 patients were treated. Mean 
patients’ age was 74 years (range 62-86). The lesions had a 
mean maximum diameter of 20 mm (range 10-36). All but 
seven patients were staged by PET-CT. 83% of cases lung 
cancer was histologically proven: 34 cases were 
adenocarcinoma, 15 squamous cell carcinomas, 5 
undifferentiated carcinomas. In the last 11 patients biopsy 
was not performed because of high risk features for 
complications and/or patient’s refusal. In this last group 81% 
had a positive PET-CT and lesion growth documented at 
subsequent CT and just two patients had only lesion growth. 
Lesion’s location were as follow: RUL 25/65 (38%), RML 2/65 
(3%), RIL 7/65 (11%), LUL 22/65 (34%) and LIL 9/65 (14%). 
Median follow-up in 61 evaluable patients was 40 months. 
Five local failure (8%) were recorded at a mean of 11,5 
months from the end of treatment (range 5.3-22). PET-CT 
SUV was the only parameter predictive for local failure, with 
a mean value of 14,2 in the recurrence group versus 6,1 in 
the recurrence-free group, respectively; p=0.03. Local 
control at 1 and 2 years were 89.6% and 86%. Median DFS was 
22.2 months and 1y-, 2y- and 3y- DFS were 66%, 47% and 40%, 
respectively. Lesions’ location according to treatment group 
was related to distant progression, which was significantly 
higher in peripheral location (p=0.004). Overall survival at 1y-
, 2y- and 3y were 97%, 77% and 66%, respectively. Treatment 
was well tolerated. G1 asymptomatic pulmonary toxicity was 
observed in 18% of cases (11/61), G2 pulmonary toxicity was 
recorded in 3% of patients. There were no pulmonary toxicity 
grade 3-4. No other toxicities were reported. 
 
Conclusion: SBRT is an effective and safe treatment for 
patients with medically inoperable stage I NSCLC. Local 
recurrence predictive value of PET-CT SUV could be 
investigated in bigger series. 
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Purpose or Objective: Radiation therapy in the palliation of 
intra-thoracic symptoms from locally advanced non-small cell 
lung cancer (NSCLC) is a significant component of workload in 
most radiotherapy departments. While most trials have 
